BC Innovations | Jul 21, 2016
Distillery Therapeutics

Therapeutics: Mucolipin 1 (TRPML1; MCOLN1); inositol polyphosphate-5-phosphatase f (INPP5F)

Renal disease INDICATION: Renal damage; renal failure Patient sample and cell culture studies suggest enhancing TRPML1 activity could help treat renal damage and failure associated with Lowe syndrome, which is caused by mutations in INPP5F...
BioCentury | Mar 5, 2007
Tools & Techniques

Expanding the HDAC envelope

A pair of recently published papers highlight two possible therapeutic areas for histone deacetylase inhibitors outside of cancer: preventing heart failure and treating spinal muscular atrophy. Several HDAC inhibitors are in Phase II trials for...
Items per page:
1 - 2 of 2